Seòmar agus comataidhean

The Scottish Government’s Aviation Statement, which will be published shortly, will set out actions that the Scottish Government will take to help achieve our aviation emissions reduction targets. Our Hydrogen Innovation Scheme previously provided £150,000 of funding to Glasgow Airport for a study to explore the feasibility of a hydrogen production, storage and distribution hub that would support zero emission transport at the airport. The Scottish Government has also provided grant funding to Edinburgh Airport to support its low carbon energy system.

The Scottish Government does not hold the detail of this funding. Local decisions on how to allocate funding is the responsibility of NHS Boards.

Public Health Scotland (PHS) collects data and provides analysis on NHS spending and the cost of running services across the 14 territorial health boards, the Golden Jubilee, and the State Hospital. This information is published annually in the Scottish Health Service Costs release (‘Costs Book’).

The data has a breakdown of Hospital, Community, Family Health Services, and subsequent breakdown into sub-categories, however it does not specifically provide funding in preventative and early interventions (also note the difference between expenditure per Cost Book and funding per the question).

The Scottish Government understands that Public Health Scotland intends to publish, as official statistics in development, gender identity clinic waiting times information provided by NHS Grampian, NHS Greater Glasgow and Clyde, NHS Highland and NHS Lothian in late summer 2024. This will be subject to the necessary data quality and completeness standards being met.

The Scottish Government welcomes the publication, on 10 April, of the final report and recommendations of the NHS England-commissioned Independent Review of Gender Identity Services for Children and Young People, chaired by Dr Hiliary Cass (‘the Cass Review’).

The findings of the review, and the associated systematic review papers, are being closely considered by both the Scottish Government and Health Boards in Scotland in the context of how such healthcare is best delivered here.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

The adaptive framework under the new Bill will enable tailored provisions and support to be implemented to support our food producers and we continue to co-develop effective policies to deliver the Vision for Agriculture. As a framework Bill it will not set thresholds which could restrict future flexibility.

How these powers will be used are set out in the Bills associated Policy Memorandum and Explanatory notes .

Future eligibility criteria will be co-developed with partners through the Ag Reform Programme.

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

In the context of the provision of gender identity healthcare to children and young people, I refer the member to question S6O-03286 on 28 March 2024. which is available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/official-report/search-what-was-said-in-parliament .

The Scottish Government does not routinely hold or collate this information. This information should be requested from the relevant Health Boards.

All Peatland ACTION delivery partners are subject to relevant Scottish Contracts Legislation.

NatureScot managed Peatland ACTION funding on an annual basis until FY 2021-2022. In order to increase our restoration rates, the Scottish Government made the decision to directly fund selected delivery partners given their proven delivery of restoration work through the existing Peatland ACTION funding model.

This was intended to empower these delivery partners to meet the Scottish Government’s programme targets within their own systems of accountability and management, directing funding streams to the most efficient delivery channels to maximise restoration rates.

The Peatland ACTION direct delivery partners are: Cairngorms National Park Authority, Forestry and Land Scotland, Loch Lomond & The Trossachs National Park Authority, NatureScot and Scottish Water.

NatureScot managed Peatland ACTION on an annual basis until 2021 when funding was then allocated to the other Delivery Partners direct from Scottish Government.

For information on any sub-contracted delivery partners please contact the aforementioned Peatland ACTION Delivery Partners.

In the context of specialist provision of gender identity healthcare to children and young people, since publication of its Strategic Action Framework for Gender Identity Service improvement in December 2021, the Scottish Government has maintained an extensive dialogue with NHS Health Boards in Scotland on how to collectively work to improve healthcare provision in this sphere.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

The Scottish Government and NHS Scotland are proactively engaged with NHS England and its commissioned research study on puberty-suppressing hormones as a treatment option for gender dysphoria. This is being delivered by the National Institute for Health Research (NIHR). The Scottish Government and the NHS in Scotland are currently observers to that ongoing study development process, however consideration by NHS partners of what further engagement with this study may be appropriate is ongoing, as the scope of the research continues to be developed and defined by NIHR.